Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00732069 · ClinicalTrials.gov registry record · Phase 2

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

A Phase 2 study, sponsored by Vanderbilt University.

Completed
Registry status
Phase 2
Development phase
19
Enrollment target

NCT00732069 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00732069, a Phase 2 study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Phase 2
Development phase
19 participants
Enrollment target

Study Summary

Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the study is to measure certain chemicals in the blood and see how those chemicals may change during hemodialysis when certain drugs are given.

Interventions

  • DRUG Placebo
  • DRUG Ramipril
  • DRUG Valsartan

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2008-08
Est. Completion 2011-12
Phase Phase 2

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT00732069

The ClinicalTrials.gov registry entry for NCT00732069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00732069 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00732069 about?

NCT00732069 is a clinical study titled "Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis". Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the s...

What is the current status of trial NCT00732069?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2008-08. Estimated completion is 2011-12.

What interventions are being tested in trial NCT00732069?

The interventions under investigation include: Placebo (DRUG), Ramipril (DRUG), Valsartan (DRUG).

Who is sponsoring clinical trial NCT00732069?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.